← The record

MupirocinAPO-MUPIROCIN

Recommended Infectious diseaseAuthority RequiredNot applicable line 💬 consumer voice

Treatment of nasal colonisation of staphylococcus aureus infection (including MRSA) in Aboriginal and Torres Strait Islander persons.

1
Submissions
2019–19
On the record
ICER range
Not modelled
Cost basis

Decisions on record

3 decisions
  • Meeting Jul 2019 Recommended Staphylococcus aureus infection
  • Meeting Mar 2009 Recommended Antibiotic ointment no PSD
  • Meeting Mar 2007 Deferred Topical antibacterial no PSD

Access path

1 submission · public record
  1. TGA registered · APO-MUPIROCIN

    TGA label narrower than the PBS population

  2. Jul 2019
    Recommended · restricted

    vs mupirocin 2% nasal ointment, 3g (Bactroban®)

  3. PBS listing · Authority Required
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
5.1 The PBAC recommended the Section 85 Authority Required (STREAMLINED) listing of a new presentation of mupirocin, in the form 2% nasal ointment 5g (Medsurge) as an alternative to the currently listed mupirocin 2% nasal ointment, 3g (Bactroban®) for the treatment of nasal colonisation of staphylococcus aureus infection in Aboriginal and Torres Strait Islander persons.PSD · Jul 2019
5.2 The PBAC noted that the TGA had accepted that bioequivalence had been established between the Medsurge mupirocin nasal ointment, 5g and the Bactroban®, 3g products.PSD · Jul 2019

Cost-effectiveness

Not modelled — minor submission (new pack size of existing drug). Cost-minimisation approach only; no economic evaluation conducted.

Cost-effectiveness accepted

Decision context

PopulationAboriginal and Torres Strait Islander persons with nasal colonisation of staphylococcus aureus (including MRSA).

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Jul 2019 Recommended · restricted mupirocin 2% nasal ointment, 3g (Bactroban®) Cost-minimisation · Cost-minimisation

Consumer voice

Jul 2019

No consumer comments were received for this item.

The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricted subsidy to Aboriginal and Torres Strait Islander persons only; TGA label applies to all populations.